Announcements Trials
Browse Landscape

Phase

Phase 2 24Phase 1/2 16Phase 1 6Phase 3 5Phase 2/3 2Phase NA 1Phase EARLY_PHASE1 1

Status

Completed 129Unknown 66Recruiting 64Active not recruiting 44Terminated 28Not yet recruiting 24Withdrawn 5Suspended 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Stomach Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 1Motor Activity 1Gallbladder Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Cisplatin 22Carboplatin 15Radiotherapy 13Paclitaxel 11Gemcitabine 10Rituximab 9Fluorouracil 9Drug Therapy 6Dexamethasone 5Cyclophosphamide 5Capecitabine 5Bevacizumab 5Vinorelbine 4Pemetrexed 4Nivolumab 4Methotrexate 4Etoposide 4Docetaxel 4Bendamustine Hydrochloride 4spartalizumab 3pertuzumab 3pembrolizumab 3fludarabine 3Vincristine 3Trastuzumab 3Surgical Procedures, Operative 3Standard of Care 3Prednisone 3Oxaliplatin 3Lenalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Withdrawn × Capecitabine × Clear all
NCT04488159 2024-09-20

iMAGINE

Medical University of Vienna

Phase 3 Withdrawn
Gastrointestinal

Colonic Neoplasms, Motor Activity

NCT04859582 2021-12-16

KEYNOTE-859

Merck Sharp & Dohme LLC

Phase 3 Withdrawn
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT03579758 2020-06-05

Chemotherapy Before & After Surgery in Patients With Resectable Gallbladder Cancer

Emory University

Phase 3 Withdrawn
Gastrointestinal

Gallbladder Neoplasms

NCT01470742 2019-12-30

Trial Comparing Capecitabine Plus Oxaliplatin (XELOX) and Capecitabine (X) as First-line Chemotherapy in Elderly Patients With Advanced Gastric Cancer

Samsung Medical Center

Phase 3 Withdrawn
Gastrointestinal

Stomach Neoplasms

NCT01245582 2011-11-09

SECOX

Sanofi

Phase 3 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡